These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23042614)

  • 1. Personalized medicine benefits patients in early trials: matching targeted therapies with gene mutations is associated with better outcomes, even in phase 1 studies.
    Printz C
    Cancer; 2012 Oct; 118(20):4911-2. PubMed ID: 23042614
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized oncology: genomic screening in phase 1.
    Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
    APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 4. Genomics, personalized medicine and cancer practice.
    Dancey J
    Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hotspot oncomutations: implications for personalized cancer treatment.
    Myers MB; Wang Y; McKim KL; Parsons BL
    Expert Rev Mol Diagn; 2012 Jul; 12(6):603-20. PubMed ID: 22845481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personalized therapy].
    Hallek M; Wolf J
    Internist (Berl); 2013 Feb; 54(2):145-6. PubMed ID: 23371256
    [No Abstract]   [Full Text] [Related]  

  • 8. The genetic basis for cancer treatment decisions.
    Dancey JE; Bedard PL; Onetto N; Hudson TJ
    Cell; 2012 Feb; 148(3):409-20. PubMed ID: 22304912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine: the medicine of tomorrow. Foreword.
    Tremblay-Servier M
    Metabolism; 2013 Jan; 62 Suppl 1():S1. PubMed ID: 23018144
    [No Abstract]   [Full Text] [Related]  

  • 10. Biospecimen banking: the pathway to personalized medicine for patients with cancer.
    Scolyer RA; Thompson JF
    J Surg Oncol; 2013 Jun; 107(7):681-2. PubMed ID: 23280671
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
    Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early phase clinical trials in pediatric hematology and oncology.
    Corbacioglu S
    Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology-driven phase II trials: what is the optimal model for molecular selection?
    Andre F; Delaloge S; Soria JC
    J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
    [No Abstract]   [Full Text] [Related]  

  • 16. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Personalized therapeutic targeting by exome analysis].
    Lamy A; Angot E; Sabourin JC
    Ann Pathol; 2012 Nov; 32(5 Suppl):S44-5. PubMed ID: 23127937
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic.
    Stricker T; Catenacci DV; Seiwert TY
    Semin Oncol; 2011 Apr; 38(2):173-85. PubMed ID: 21421108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Personalized medicine and molecular targets of drugs].
    Nishiyama M
    Nihon Rinsho; 2010 Oct; 68(10):1917-22. PubMed ID: 20954340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.